Article Text

PDF
Fifteen-minute consultation: diagnosis and management of congenital CMV
  1. Tejshri Shah1,
  2. Suzanne Luck2,3,
  3. Mike Sharland3,
  4. Seilesh Kadambari3,
  5. Paul Heath3,
  6. Hermione Lyall1
  1. 1Paediatric Infectious Diseases, St. Mary's Hospital, Imperial College NHS Healthcare Trust, London, UK
  2. 2Department of Paediatrics, Kingston Hospital NHS Foundation Trust, London, UK
  3. 3Paediatric Infectious Diseases Research Group, St George's University of London, London, UK
  1. Correspondence to Dr Tejshri Shah, Department of Paediatric Infectious Diseases, St. Mary's Hospital, Imperial College NHS Healthcare Trust, London, UK; tejshrishah{at}gmail.com

Abstract

Congenital cytomegalovirus (cCMV) infection can result in permanent neurological problems and is a potentially preventable cause of sensorineural hearing loss in the UK. There is an urgency to diagnose and assess cCMV as antiviral treatment and has only been shown to be effective if started in the first 4 weeks of life. A recent randomised controlled trial of 6 months of treatment using oral valganciclovir has shown modest benefit in preventing hearing deterioration and in improving some neurodevelopmental outcomes. Parents and clinicians need to make a timely and informed choice regarding antiviral treatment and ensure that relevant non-pharmaceutical interventions are considered. This paper brings together the current evidence regarding the diagnosis and treatment of cCMV, consensus from two paediatric infectious diseases centres and outlines research priorities.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.